TRIMETHOPRIM tablet

Nchi: Marekani

Lugha: Kiingereza

Chanzo: NLM (National Library of Medicine)

Viambatanisho vya kazi:

TRIMETHOPRIM (UNII: AN164J8Y0X) (TRIMETHOPRIM - UNII:AN164J8Y0X)

Inapatikana kutoka:

Novitium Pharma LLC

Njia ya uendeshaji:

ORAL

Dawa ya aina:

PRESCRIPTION DRUG

Matibabu dalili:

To reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets and other antibacterial drugs, trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Proteus mirabilis , Klebsiella pneumoniae , Enterobacter species, and coagulase-negative Staphylococcus species, including S. saprophyticus . Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of

Bidhaa muhtasari:

Trimethoprim Tablets, USP 100 mg: White, round, convex tablet, debossed “N”, scored, “541” on one side and plain on the other side, in bottles of 100. NDC 70954-541-10 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP with a child-resistant closure (as required).

Idhini hali ya:

Abbreviated New Drug Application

Tabia za bidhaa

TRIMETHOPRIM - TRIMETHOPRIM TABLET
NOVITIUM PHARMA LLC
----------
TRIMETHOPRIM TABLETS, USP
RX ONLY
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of
trimethoprim tablets and other antibacterial drugs, trimethoprim
tablets should be used
only to treat or prevent infections that are proven or strongly
suspected to be caused
by bacteria.
DESCRIPTION
Trimethoprim is a synthetic antibacterial available in tablet form for
oral administration.
Each scored white tablet contains 100 mg trimethoprim.
Trimethoprim is
5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine. It is a
white
to light yellow, odorless, bitter compound with a molecular weight of
290.32 and the
molecular formula C
H
N O
The structural formula is:
INACTIVE INGREDIENTS
Anhydrous Lactose, Microcrystalline cellulose, Pregelatinized Starch,
Sodium Starch
Glycolate Type A, Magnesium Stearate.
FDA approved dissolution test specifications differ from USP.
14
18
4
3.
CLINICAL PHARMACOLOGY
Trimethoprim is rapidly absorbed following oral administration. It
exists in the blood as
unbound, protein-bound, and metabolized forms. Ten to twenty percent
of trimethoprim
is metabolized, primarily in the liver; the remainder is excreted
unchanged in the urine.
The principal metabolites of trimethoprim are the 1- and 3-oxides and
the 3'- and 4'-
hydroxy derivatives. The free form is considered to be the
therapeutically active form.
Approximately 44% of trimethoprim is bound to plasma proteins.
Mean peak serum concentrations of approximately 1.0 mcg/mL occur 1 to
4 hours after
oral administration of a single 100 mg dose. A single 200 mg dose will
result in serum
levels approximately twice as high. The half-life of trimethoprim
ranges from 8 to 10
hours. However, patients with severely impaired renal function exhibit
an increase in the
half-life of trimethoprim, which requires either dosage regimen
adjustment or not using
the drug in such patients (see DOSAGE AND ADMINISTRATION). During a
13-week
study of trimethoprim administered at